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Patients with severe symptomatic mitral regurgitation have a poor prognosis if left
untreated. In those patients who are not eligible for mitral valve surgery, percutaneous
edge-to-edge repair may improve clinical outcomes. Recent clinical trials have added to
our knowledge and provide interesting insights into the management of such patients.
With an increasingly aging global population, these technologies are likely to represent an
important treatment option. This mini-review will examine the technology, the evidence
and the latest developments in percutaneous mitral edge-to-edge repair.
Keywords: percutaneous mitral repair, mitral valve, mitral regurgitation (MR), MitraClip (MC), transcatheter mitral
valve (MV) repair
INTRODUCTION
It has been estimated that nearly 50% of patients with severe symptomatic mitral regurgitation
(MR) are not referred for surgery, mainly because of age, and reduced left ventricular function
resulting in high surgical risk (1). Conversely, 62% of patients with ischaemic secondary MR
and systolic heart failure are dead within 5 years (2). In this light, the MitraClip (MC) mitral
valve repair system (Abbott Vascular, Abbott Park, Illinois, USA) has taken center stage as a
treatment option, particularly in the context of an aging population. The obvious advantages of
a percutaneous approach are reduced invasiveness and rapid recovery. The first procedure was
performed in 2003, CE mark obtained in 2008 and FDA approval for the treatment of primary
MR in 2013. Transcatheter mitral valve (MV) repair compared with conventional MV surgery
has demonstrated similar 5-year mortality in the Endovascular Valve Edge-to-Edge Repair Study
II (EVEREST II) albeit at the cost of treatment efficacy compared to surgical MV repair or
replacement in patients with predominantly primary MR (3). Surgical treatment of secondary MR
is not well established, therefore the recently published results of the randomized MITRA-FR and
COAPT trials examining the additive benefits of MC on top of medical therapy specifically in
secondary MR populations were highly anticipated (4, 5). While COAPT showed a 47% relative
risk reduction of the primary endpoint (all hospitalizations for heart failure at 24 months), as well
as a lower mortality after 2 years of follow-up (29.1 vs. 46.1%; hazard ratio, 0.62; 95% CI, 0.46–0.82;
p < 0.001), no significant difference between groups were found in the smaller MITRA-FR study.
These diametrically opposing results can be explained by diverging patient characteristics. This
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SURGICAL TREATMENT
Current European guidelines advocate surgical treatment for
symptomatic severe primary MR as a class I indication.
Surgery is also recommended in asymptomatic MR in the
presence of predictors of worse outcome (atrial fibrillation,
left ventricular ejection fraction ≤60%, or LVESD ≥45mm or
systolic pulmonary pressure ≥50 mmHg) or if there is a low
surgical risk and a high chance of durable repair in patients
with a LVESD ≥40mm and either a flail leaflet or an enlarged
left atrium (6). Although no randomized data are available,
surgical repair is preferred over replacement where anatomically
possible and is associated with a low recurrence in primary MR
(90% of surviving patients after 20 years remain free of severe
MR). Observational studies suggest improved clinical outcomes
compared with MV replacement (7, 8).
In contrast, surgical repair of secondary MR has less
favorable outcomes with increased perioperative mortality and
MR recurrence rates as high as 60% within 2 years (9). In
patients undergoingmitral-valve repair or replacement for severe
ischemic mitral regurgitation, no significant between-group
difference in left ventricular reverse remodeling or survival was
seen at 2 years. Mitral regurgitation recurred more frequently
in the repair group, resulting in more heart-failure–related
adverse events and cardiovascular admissions. However, reverse
remodeling at 2 years was observed after successful repair rather
than replacement (10).
The Alfieri surgical edge to edge repair operation was designed
to reduce MR by creating a double orifice from the placement
of a stitch joining the free edge of the anterior and posterior
mitral valve leaflets (11). The benefit of the operation was
effective reduction of MR using a relatively easy and reproducible
technique, although it is often combined with annuloplasty for a
more durable result.
Despite surgical treatments being available, it is estimated
nearly 50% of patients with severe MR are not referred due to
prohibitively high risk as a result of age and comorbidity (12).
In those older and more comorbid patients undergoing surgical
treatments for MR there is generally no increase in long-term
survivability and uncertain benefit on quality of life (13). A
less invasive treatment option would therefore be particularly
appealing for this patient group.
PERCUTANEOUS MITRAL LEAFLET
REPAIR
The success of transcatheter aortic valve replacement has
demonstrated the benefits of innovation in the domain of the
treatment of structural heart disease. As this field grows, the next
frontiers are effective interventional treatments for the mitral
and tricuspid valves. The only percutaneous leaflet repair system
with both FDA and CE mark approval is the MitraClip (Abbott,
Abbott Park, Illinois). Its competitor, the PASCAL System
(Edwards Life sciences, Irvine, California), recently obtained CE
mark and a pivotal trial is currently underway aiming for FDA
approval. Both systems aim to approximate the mitral valve
leaflets to reduce MR.
PRE-PROCEDURAL PLANNING
Pre-procedural planning for MC includes a comprehensive
echocardiographic assessment for a precise depiction of the
underlying mechanism for regurgitation, as well as grading of
MR severity.
On transthoracic echocardiography (TTE), biventricular size
and systolic function, left atrium size, other significant valvular
disease and estimation of pulmonary pressure based on the
Guideline recommended imaging windows and parameters
should be obtained (14).
Transesophageal echocardiography (TEE) is the mainstay
for MR intervention screening because of its key role in
intraprocedural guidance. A careful examination of the
mechanism of MR and quantitative assessment of MR degree
of severity should be reported. In addition to the standard
2D echocardiographic views, utilization of advanced imaging
is particularly helpful to determine the presence of anatomic
abnormality. The use of multiplane imaging allows a systematic
visualization of all MV scallops, from the medial to lateral
aspects of the MV (Figure 1). An en-face view of the atrial side
of the entire MV (surgeon’s view) and adjacent structures is
possible using 3D imaging. Flail and prolapse segments, the
location of clefts, deep indentations, perforations and significant
malcoaptation gaps may bemore apparent and easier to visualize.
In addition, MV area can more precisely be measured (Figure 2).
Current European Guidelines recommend a multiparametric
approach for the diagnosis of severe MR including semi-
quantitative parameters (vena contracta ≥7mm, systolic flow
reversal in the pulmonary veins, mitral inflow dominant E-wave
≥1.5 m/s, and MR velocity (CWDoppler) TVI mitral/TVI aortic
>1.4) and quantitative parameters (effective regurgitant orifice
area (EROA) and the regurgitant volume (R Vol), which is ≥
40 mm² and ≥ 60ml for primary MR. In secondary MR, an
EROA ≥ 20 mm² and R Vol ≥ 30ml have been shown to have
a prognostic value and therefore proposed to indicate severe
disease in the European Guidelines, but not in the corresponding
Guidelines of the American Society of Echocardiography (2, 6,
15). Quantification of MR severity should be performed using
2D or 3D proximal isovelocity surface area (PISA) method or
preferably 3D vena contracta area.
Both TTE and TEE should be reviewed by the Heart Team
to confirm eligibility and intraprocedural approach to MV
repair. Agreement should be made as to the precise location for
device placement, number of device, and treatment strategies,
particularly withmore challenging anatomy as defined inTable 1.
ABBOTT MITRACLIP: THE PROCEDURE
TheMitraClip device has been implanted in over 100,000 patients
worldwide. It is introduced percutaneously via a 24 French
orientable guiding catheter from the femoral vein using a
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FIGURE 1 | Multiplane view of the mitral valve. Mid-esophageal biplane views (left panel: 60 degree view, right panel: 150 degree view) of the mitral valve leaflets. The
blue arrow demonstrates the medial aspect of the mitral valve, the orange arrow, the central aspect and the red arrow, the lateral aspect of the mitral valve.
FIGURE 2 | Measurement of the 3D mitral valve area (MVA) by transoesophageal echocardiography in a patient with severe MR; the MVA in this case was 5.48 cm²
indicating suitability for percutaneous mitral valve repair.
superior and posterior trans-septal puncture to access the left
atrium. A steerable clip delivery catheter enables orientation
of the clip whilst real-time 3D transoesophageal echo allows
precision targeting of the free edges of the opposing leaflets at
the site of regurgitation. The device is then advanced into the
left ventricle and while pulling back the catheter, the mitral valve
leaflets are grasped. Once optimal grasping has been undertaken,
the clip is closed creating a double orifice. Transoesophageal echo
is used to assess for adequate leaflet insertion, residual MR and
new trans-valvular gradients avoiding mitral stenosis prior to
final deployment. Direct measurement of LA mean pressure and
V wave provides complementary hemodynamic data to guide
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TABLE 1 | Anatomical considerations for percutaneous mitral leaflet repair.
Favorable Unfavorable/contraindicated
Moderate-severe or severe MR Commissural lesions
A2-P2 defect Clefts
Prolapse width <15mm Short posterior leaflet (<5mm)
Flail gap <10mm Mitral valve orifice area < 3.5 cm2
Mitral valve orifice area > 4 cm2 Severe calcification of grasping zone
Mobile length of the posterior
leaflet ≥ 7mm
Leaflet perforations
Mitral stenosis with mean gradient ≥5 mmHg at
baseline
Active endocarditis or rheumatic heart disease
treatment decision-making. Multiple clips can be implanted to
optimize imperfect results on a case by case basis if gradients and
anatomy allow. Hemodynamics usually remain very stable during
the procedure and recovery time is short.
NEWEST ITERATION: MITRACLIP XTR
There is currently a new version of the clip, the MitraClip XTR
(MC XTR), which is similar to the first generation and NT
versions of the MC in that it consists of a 24 French steerable
guide catheter and a steerable clip delivery system (CDS). The
MC XTR has a 5mm longer clip grasping width due to longer
arms (22 vs. 17mm comparedwith theNTR). The transition zone
between the delivery sheath and the CDS has been reinforced
to improve stability during rotation of the CDS. The steerable
sleeve is also more responsive to the rotation of the M-knob. The
working length of the system has been increased by 1.5 cm and
changes to the mechanism and material of the lock line enable
operation of the system in the “unlocked” position. Finally a new
Nitinol rather than Elgiloy gripper line enables a deeper gripper
drop and grasping angle. Ultimately, the MC XTR may enable
easier and quicker leaflet grasping, reduce the number of clips
required and expand percutaneous treatment to patients with less
favorable anatomy.
On the other hand, grasping more tissue may result in
additional tension on the leaflets that concentrates at the tip
of the clip arms. This may provoke leaflet damage, especially
in patients with calcifications, fragile, or thin appearing leaflets.
Moreover, due to the increased length of the clip arms, the risk
of entrapment in the subvalvular apparatus is certainly higher,
particularly when treating commissural lesions. According to a
recently published multicenter experience in 107 patients treated
with the MC XTR, procedural success was high with MR≤2+
in 93% of the patients and ≤1+ in 77%. However, four patients
had leaflet damage requiring surgical correction during the same
hospitalization (16). Thus, the use of the XTR system should be
evaluated based on individual anatomy, rather than as a default
strategy. Although requiring further evaluation, the combination
of different clip sizes may represent a valuable treatment option
in patients on whom valve area/gradient is borderline (Figure 3).
It is anticipated that future iterations of the MitraClip will allow
independent leaflet grasping.
FIGURE 3 | (A) Fluoroscopic appearance of a successfully implanted XTR and
NTR clip. (B,C) 3D transoesophageal echocardiographic view and Doppler,
respectively, providing an en face view of the valve from the same case after
implantation. (D) MitraClip versions currently available.
THE EDWARDS PASCAL MITRAL REPAIR
SYSTEM (EDWARDS LIFESCIENCES,
IRVINE, CA, USA)
The Edwards PASCAL Transcatheter Valve Repair System has
been designed to address some of the limitations of previous
systems. It is intended to reduce the tension on the valve
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FIGURE 4 | (A,B) Positioning of the PASCAL device in the mitral valve. (C,D) Grasping of the two leaflets. (E,F) Transoesophageal Doppler image of a case of severe
MR before and after leaflet repair with the PASCAL device, respectively.
leaflets by introducing a 10mm central spacer within the MV
regurgitant orifice. The paddles of the implant are also wider
and curved to further reduce tension and the system allows for
independent grasping of the leaflets. This may be particularly
useful in the presence of a large prolapse gap (Figure 4) or
in patients with retraction or tethering of the posterior leaflet.
The device is also designed to be easier navigated in the left
atrium and offers a higher degree of steerability. A first-in-
human feasibility experience of the device has been described
from a series of 23 compassionate use cases (17). These early
data were encouraging with MR ≤2+ in 97% of the patients
at discharge and without elevated gradients despite a larger
device size.
The CLASP study is a multicenter, prospective trial of the
PASCAL system in 62 patients with significant MR despite
medical therapy, with independent adjudication of clinical events
and central echo core lab. Mean age was 76.5 years, NYHA class
II/IV in 51.6%, with 56% FMR, 36% DMR, and 8% mixed MR
etiology. At 30 days, the major adverse event rate was 6.5%, with
all-cause mortality of 1.6% (18). Overall, 98% of patients had
MR ≤ 2+, and 86% had MR ≤ 1+, with 85% in NYHA Class
I/II; significant improvements were also observed in 6min walk
distance and KCCQ scores. Based on these promising results,
the PASCAL system gained CE mark in early 2019. The pivotal
CLASP IID/F randomized trial has begun enrolment, and will
compare the efficacy and safety of PASCAL vs. MitraClip in
patients with significant DMR or FMR, using a non-inferiority
study design.
EVIDENCE FROM RANDOMIZED TRIALS
EVEREST II (NCT00209274, Endovascular Valve Edge-to-Edge
REpair Study) was the first randomized trial to examine the
MitraClip system in 279 patients with moderate-to-severe or
severe MR, comparing percutaneous therapy to conventional
surgery in a respective 2:1 ratio (19). Published in 2011,
this was a very early experience with the system for many
of the recruiting sites. The percutaneous intervention arm
demonstrated superior safety with similar improvements in
clinical outcomes although was less effective at reducing MR
compared to surgery at 1 year. The primary end point for
efficacy (freedom from death, MV surgery, reintervention, and
moderate-to-severe MR) was 55% in the MitraClip group and
73% in the surgical group at 12 months (p = 0.007). Major
adverse events occurred in 15% of patients in the MitraClip
group and 48% of patients in the surgical group at 30 days
(p < 0.001). The 5 year follow-up from this study found
the composite endpoint in the as-treated population was 44.2
vs. 64.3% in the percutaneous repair and surgical groups,
respectively (p = 0.01) driven primarily by more MR and more
subsequent mitral surgery in the percutaneous arm. Rates of
surgery and moderate-to-severe MR were comparable between
groups beyond 6 months, affirming the durability of both
techniques. Notably, only 27% of the patients in this trial had
secondary MR.
The French MITRA-FR study randomized 307 patients
with symptomatic left ventricular dysfunction and significant
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secondary MR to either medical therapy or medical therapy
combined with the MitraClip procedure (5). 92% of patients
achieved an MR grade ≤2+ immediately after the procedure
while there was no difference in the primary outcome of all-
cause death and unplanned re-hospitalization for heart failure
at 1 year which occurred in 55% of the intervention group
and 51% of the control group (odds ratio [OR], 1.16; 95%
confidence interval [CI] 0.73–1.84; p = 0.53). The mortality
rate was 24.3% in the intervention group vs. 22.4% in the
control group (hazard ratio [HR], 1.11; 95% CI 0.69–1.77)
at 12 months. As an important limitation, it has to be
mentioned that a significant amount of follow-up data on
echocardiographic outcome and functional status at 12 months
were missing.
The presentation of the results from MITRA-FR were closely
followed by the North American COAPT trial which randomized
614 patients with symptomatic heart failure and moderate-to-
severe or severe secondary MR to medical therapy or medical
therapy and MitraClip repair (4). The primary outcome was the
rate of hospitalization for heart failure within 24 months which
was 35.8% per patient-year in the device group as compared
with 67.9% in the control group (HR, 0.53; 95% CI, 0.40–
0.70; p < 0.001). Moreover, the powered secondary end point
of death from any cause within 24 months was significantly
lower occurring in 29.1% of the patients in the device group as
compared with 46.1% in the control group (HR, 0.62; 95% CI,
0.46–0.82; p < 0.001). The number of patients needed to treat
to prevent 1 hospitalization was 3 and to prevent 1 death was
6. All prespecified secondary endpoints including quality of life
and functional assessments were significantly improved in the
MitraClip arm.
While both trials examining MC in the context of secondary
MR produced different results, there were major differences
between the two trials. Firstly, due to differing definitions of
severe functional mitral regurgitation between European and
North American guidelines, mitral regurgitation was more severe
in the COAPT trial than in the MITRA-FR trial (mean EROA
of 41 vs. 31 mm2). In addition, the indexed left ventricular end-
diastolic volumes were smaller in COAPT as compared with
MITRA-FR (101 ± 34 vs. 135 ± 35 ml/m2). Another difference
between the trials may have been increased aggressiveness of the
guideline directed medical therapy delivered to the patients in
COAPT which was overseen by the screening committee. Taken
together, this might mean the patients in COAPT had worse
MR with relatively more preserved left ventricles representing a
group a patients that benefit most from percutaneous edge-to-
edge repair.
Secondly the number of patients receiving more than one clip
was higher in COAPT possibly explaining the higher proportion
of moderate-to-severe or severe residual MR at 1 year in MITRA-
FR (17 vs. 5% in COAPT).
FUTURE DIRECTIONS
There are a number of questions still remaining with regards to
percutaneous leaflet repair:
1. Empirical use of antiplatelet therapy for stroke prevention
after the procedure has been advocated without any trial
evidence. Recent registry data suggests the use of a NOAC
with a single antiplatelet may prove beneficial as compared
with antiplatelet therapy alone, especially in the first year post
implantation (20). Randomized data would be needed to more
accurately define the answer to this important question.
2. The evaluation of percutaneous edge-to-edge repair in cases
of cardiogenic shock resulting from acute MR would be
an interesting avenue to explore, particularly in the setting
of subacute myocardial infarction where surgical repair
remains hazardous.
3. The objective echocardiographic grading of post-
procedural residual MR is very challenging and requires
further validation.
4. The management of the atrial septal defect created during
MitraClip has to be further clarified.
5. Continuous left atrial pressure monitoring is a promising
but still not well-standardized method to evaluate outcome
of repair.
6. Further data is required to understand what is the place of
the PASCAL device within treatment options and whether
it can tackle complex anatomy such as larger flail segments,
shorter posterior leaflets, or cases involving mitral annular
calcification; this may be answered by a future head to
head trial.
The development of newer devices and iterations in the field
of percutaneous leaflet repair may expand the spectrum of
anatomies that can be treated. Patients with primary MR and
favorable anatomy who are inoperable or at high risk for surgery,
can reasonably be offered percutaneous mitral valve repair. In
secondary MR, patient selection seems to be of paramount
importance to optimize individual outcomes. Volume overload
from excessive secondary MR should no longer be thought of
as an innocent bystander but rather a contributing factor to
poor outcomes in patients with heart failure. Based on the
data available, guideline directed medical therapy for heart
failure should be optimized with cardiac resynchronization
where appropriate prior to consideration of percutaneous mitral
valve repair. If despite these measures symptomatic moderate-
severe or severe functional MR remains, an early approach
to treatment should be considered before further deterioration
of ventricular performance occurs. The early detection and
appropriate management of these patients in a multidisciplinary
Heart Team is crucial to allow timely interventional treatment.
Identification of factors predicting response to the therapy is
expected to be a topic of future research. Potential meaningful
parameters may include the proportionality of MR related
to ventricular dilation, the presence of myocardial fibrosis
precluding ventricular remodeling, as well as the use of strain
echocardiography to better appreciate myocardial function (21).
While new device iterations allow novel features such as
independent grasping or increasing arm dimensions, they also
introduce new challenges such as possible asymmetric grasping
resulting in residual MR or excessive leaflet tension and thus
require a further learning curve for optimal use.
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With the recent advances in technology and an expanding
knowledge base from carefully conducted randomized clinical
trials, we are already glimpsing into a future where percutaneous
therapies have an important role in the management of mitral
valve disease and heart failure.
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